vs
Enhabit, Inc.（EHAB）与和黄医药（HCM）财务数据对比。点击上方公司名可切换其他公司
和黄医药的季度营收约是Enhabit, Inc.的1.0倍（$270.8M vs $270.4M），和黄医药净利率更高（0.7% vs -14.3%，领先15.0%），Enhabit, Inc.同比增速更快（4.7% vs -16.5%），和黄医药自由现金流更多（$3.4M vs $3.3M）
Enhabit, Inc.是总部位于美国得克萨斯州达拉斯的居家护理与临终关怀服务提供商，目前在全美34个州运营255个居家护理站点与110个临终关怀站点，业务集中在得克萨斯、亚拉巴马、佛罗里达、佐治亚、俄克拉荷马与密西西比，是美国第四大居家护理服务商，也是头部临终关怀服务商，2022年由恩compass健康拆分居家护理与临终关怀业务拆分成立。
和黄医药是一家国际化生物制药企业，专注于肿瘤、免疫类疾病的靶向疗法与免疫疗法的研发、生产及商业化，核心市场覆盖中国及全球多个国家地区，已有多款肿瘤治疗药物上市，后期临床管线储备丰富。
EHAB vs HCM — 直观对比
营收规模更大
HCM
是对方的1.0倍
$270.4M
营收增速更快
EHAB
高出21.3%
-16.5%
净利率更高
HCM
高出15.0%
-14.3%
自由现金流更多
HCM
多$56.0K
$3.3M
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $270.4M | $270.8M |
| 净利润 | $-38.7M | $2.0M |
| 毛利率 | — | 37.7% |
| 营业利润率 | -12.3% | -13.2% |
| 净利率 | -14.3% | 0.7% |
| 营收同比 | 4.7% | -16.5% |
| 净利润同比 | 15.9% | -83.6% |
| 每股收益（稀释后） | $-0.76 | $0.00 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EHABHCM
| Q4 25 | $270.4M | $270.8M | ||
| Q3 25 | $263.6M | — | ||
| Q2 25 | $266.1M | $277.7M | ||
| Q1 25 | $259.9M | $324.5M | ||
| Q4 24 | $258.2M | — | ||
| Q3 24 | $253.6M | — | ||
| Q2 24 | $260.6M | $305.7M | ||
| Q1 24 | $262.4M | — |
净利润EHABHCM
| Q4 25 | $-38.7M | $2.0M | ||
| Q3 25 | $11.1M | — | ||
| Q2 25 | $5.2M | $455.0M | ||
| Q1 25 | $17.8M | $11.9M | ||
| Q4 24 | $-46.0M | — | ||
| Q3 24 | $-110.2M | — | ||
| Q2 24 | $-200.0K | $25.8M | ||
| Q1 24 | $200.0K | — |
毛利率EHABHCM
| Q4 25 | — | 37.7% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 0.1% | ||
| Q1 25 | — | 48.0% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 41.1% | ||
| Q1 24 | — | — |
营业利润率EHABHCM
| Q4 25 | -12.3% | -13.2% | ||
| Q3 25 | 6.4% | — | ||
| Q2 25 | 6.3% | -1.3% | ||
| Q1 25 | 6.1% | -5.0% | ||
| Q4 24 | -16.0% | — | ||
| Q3 24 | -38.6% | — | ||
| Q2 24 | 4.3% | -9.0% | ||
| Q1 24 | 4.9% | — |
净利率EHABHCM
| Q4 25 | -14.3% | 0.7% | ||
| Q3 25 | 4.2% | — | ||
| Q2 25 | 2.0% | 163.8% | ||
| Q1 25 | 6.8% | 3.7% | ||
| Q4 24 | -17.8% | — | ||
| Q3 24 | -43.5% | — | ||
| Q2 24 | -0.1% | 8.4% | ||
| Q1 24 | 0.1% | — |
每股收益（稀释后）EHABHCM
| Q4 25 | $-0.76 | $0.00 | ||
| Q3 25 | $0.22 | — | ||
| Q2 25 | $0.10 | $0.52 | ||
| Q1 25 | $0.35 | $0.01 | ||
| Q4 24 | $-0.92 | — | ||
| Q3 24 | $-2.20 | — | ||
| Q2 24 | $0.00 | $0.03 | ||
| Q1 24 | $0.01 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $43.6M | $1.4B |
| 总债务越低越好 | $426.0M | $93.2M |
| 股东权益账面价值 | $534.0M | $1.2B |
| 总资产 | $1.2B | $1.8B |
| 负债/权益比越低杠杆越低 | 0.80× | 0.08× |
8季度趋势，按日历期对齐
现金及短期投资EHABHCM
| Q4 25 | $43.6M | $1.4B | ||
| Q3 25 | $56.9M | — | ||
| Q2 25 | $37.1M | $1.4B | ||
| Q1 25 | $39.5M | $836.1M | ||
| Q4 24 | $28.4M | — | ||
| Q3 24 | $45.7M | — | ||
| Q2 24 | $28.5M | $802.5M | ||
| Q1 24 | $36.5M | — |
总债务EHABHCM
| Q4 25 | $426.0M | $93.2M | ||
| Q3 25 | $441.5M | — | ||
| Q2 25 | $456.9M | $93.4M | ||
| Q1 25 | $467.3M | $82.8M | ||
| Q4 24 | $492.6M | — | ||
| Q3 24 | $502.9M | — | ||
| Q2 24 | $512.7M | $82.1M | ||
| Q1 24 | $526.7M | — |
股东权益EHABHCM
| Q4 25 | $534.0M | $1.2B | ||
| Q3 25 | $566.8M | — | ||
| Q2 25 | $552.4M | $1.2B | ||
| Q1 25 | $543.2M | $759.9M | ||
| Q4 24 | $523.5M | — | ||
| Q3 24 | $566.1M | — | ||
| Q2 24 | $674.3M | $740.1M | ||
| Q1 24 | $672.3M | — |
总资产EHABHCM
| Q4 25 | $1.2B | $1.8B | ||
| Q3 25 | $1.2B | — | ||
| Q2 25 | $1.2B | $1.8B | ||
| Q1 25 | $1.2B | $1.3B | ||
| Q4 24 | $1.2B | — | ||
| Q3 24 | $1.3B | — | ||
| Q2 24 | $1.4B | $1.3B | ||
| Q1 24 | $1.4B | — |
负债/权益比EHABHCM
| Q4 25 | 0.80× | 0.08× | ||
| Q3 25 | 0.78× | — | ||
| Q2 25 | 0.83× | 0.08× | ||
| Q1 25 | 0.86× | 0.11× | ||
| Q4 24 | 0.94× | — | ||
| Q3 24 | 0.89× | — | ||
| Q2 24 | 0.76× | 0.11× | ||
| Q1 24 | 0.78× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $4.4M | $8.2M |
| 自由现金流经营现金流 - 资本支出 | $3.3M | $3.4M |
| 自由现金流率自由现金流/营收 | 1.2% | 1.2% |
| 资本支出强度资本支出/营收 | 0.4% | 1.8% |
| 现金转化率经营现金流/净利润 | — | 4.21× |
| 过去12个月自由现金流最近4个季度 | $65.8M | $-96.2M |
8季度趋势，按日历期对齐
经营现金流EHABHCM
| Q4 25 | $4.4M | $8.2M | ||
| Q3 25 | $37.8M | — | ||
| Q2 25 | $10.6M | $-72.9M | ||
| Q1 25 | $17.9M | $40.3M | ||
| Q4 24 | $-4.1M | — | ||
| Q3 24 | $28.4M | — | ||
| Q2 24 | $9.6M | $-39.8M | ||
| Q1 24 | $17.3M | — |
自由现金流EHABHCM
| Q4 25 | $3.3M | $3.4M | ||
| Q3 25 | $36.2M | — | ||
| Q2 25 | $8.7M | $-82.2M | ||
| Q1 25 | $17.6M | $32.5M | ||
| Q4 24 | $-4.7M | — | ||
| Q3 24 | $27.7M | — | ||
| Q2 24 | $8.9M | $-49.9M | ||
| Q1 24 | $15.5M | — |
自由现金流率EHABHCM
| Q4 25 | 1.2% | 1.2% | ||
| Q3 25 | 13.7% | — | ||
| Q2 25 | 3.3% | -29.6% | ||
| Q1 25 | 6.8% | 10.0% | ||
| Q4 24 | -1.8% | — | ||
| Q3 24 | 10.9% | — | ||
| Q2 24 | 3.4% | -16.3% | ||
| Q1 24 | 5.9% | — |
资本支出强度EHABHCM
| Q4 25 | 0.4% | 1.8% | ||
| Q3 25 | 0.6% | — | ||
| Q2 25 | 0.7% | 3.3% | ||
| Q1 25 | 0.1% | 2.4% | ||
| Q4 24 | 0.2% | — | ||
| Q3 24 | 0.3% | — | ||
| Q2 24 | 0.3% | 3.3% | ||
| Q1 24 | 0.7% | — |
现金转化率EHABHCM
| Q4 25 | — | 4.21× | ||
| Q3 25 | 3.41× | — | ||
| Q2 25 | 2.04× | -0.16× | ||
| Q1 25 | 1.01× | 3.38× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -1.54× | ||
| Q1 24 | 86.50× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EHAB
| Third Party Payor Medicare | $111.6M | 41% |
| Third Party Payor Medicare Advantage | $67.5M | 25% |
| Hospice Segment | $63.6M | 24% |
| Third Party Payor Managed Care | $24.9M | 9% |
| Third Party Payor Medicaid | $1.7M | 1% |
HCM
暂无分部数据
